St. Jude claims its Quadripolar pacing system set the standard and a newly presented study is a strong addition to the more than 100 publications supporting the argument.
Newly cleared PROTEK Duo™ veno-venous cannula is intended for use as a single cannula for both venous drainage and reinfusion of blood via an internal jugular vein during extracorporeal life support procedures.
Ethicon is introducing three new endocutter and energy products at the 19th World Congress of International Federation for the Surgery of Obesity & Metabolic Disorders (IFSO 2014).
Medtech Titan Medtronic has acquired Dutch Neuro device developer and its novel Deep Brain Stimulation system
It's full steam ahead for Claret Medical as it announces Series B financing that will take it a long way down the road to US FDA approval, assuming its pivotal study goes to plan.
Cook Medical has initiated a recall of 696 of its CloverSnare™ 4-Loop Vascular Retrieval Snare devices because of a potential for device failure with serious consequences.
Sounds like a plan. Combine the offerings of one of the Cardiovascular big boys with wire forming company's expertise and FFR technology is likely to benefit.
Cook's peripheral drug stent, the first of its kind in China, is being conducted at up to 20 clinical sites and will enroll 175 patients with one-year follow-up.
Medtronic has gained U.S. FDA 510(k) clearance for its SHILLA™ Growth Guidance System, designed to treat spinal deformities in skeletally immature pediatric patients with severe, progressive, life-threatening, early-onset spinal deformities.
When a device is relied on to provide distraction, it's obviously alarming when it has the potential to reverse direction. The consequences are significant enough to warrant the FDA classifying Depuy Synthes' recall as Class I.
Cormatrix's aptly named CanGaroo envelope (or pouch) offers a marsupialised approach to cardiac device implantation.
CE marked earlier in the year, Medtronic's Viva CRT-P system will now be available for US patients following its newly announced FDA approval.
This is big news for Direct Flow as it needed that 23mm option to open up a new patient cohort. The avoidance of contrast media is big for the company too.
It might seem obvious that the heightened level of care provided by remote monitoring of cardiovascular conditions would result in only good things for patients. A new study, published in The Lancet, confirms it.
Even with potential sentences of up to 20 years in the offing, it's still painful for the medical device industry to see its name being sullied by fraudulent actions of a few trusted individuals.